<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00465816</url>
  </required_header>
  <id_info>
    <org_study_id>109063</org_study_id>
    <nct_id>NCT00465816</nct_id>
  </id_info>
  <brief_title>Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612</brief_title>
  <official_title>Non-inferiority of GSK Biologicals' Meningococcal Vaccine 134612 Given Concomitantly With GSK Biologicals' Twinrix™ Versus 134612 Alone and Twinrix™ Alone in Healthy Subjects Aged 11 Through 17 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study will demonstrate the non-inferiority of GSK Biologicals' meningococcal vaccine
      134612 when given in an experimental co-administration versus vaccine 134612 alone and versus
      the experimental co-administration alone in healthy subjects aged 11 through 17 years. There
      will be 3 groups in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects of groups A and B will have 4 blood samples taken, all subjects of group C will
      have 3 blood samples taken.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act,
      September 2007.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Meningococcal Polysaccharide A Serum Bactericidal Antibodies/Assay, Using Baby Rabbit Complement for Assay (rSBA-MenA), rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers</measure>
    <time_frame>At 1 month after vaccination with Nimenrix vaccine (Month 1)</time_frame>
    <description>The rSBA titers were expressed as geometric mean titers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Seroconverted for Hepatitis A</measure>
    <time_frame>At 1 month after the third dose of Twinrix vaccine (Month 7)</time_frame>
    <description>A seroconverted subject was defined as a subject with anti-Hepatitis A virus (HAV) antibody concentration greater than or equal to 15 milli-International Units per Milliliter (mIU/mL) in previously seronegative subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Seroprotected for Hepatitis B</measure>
    <time_frame>At 1 month after the third dose of Twinrix vaccine (Month 7)</time_frame>
    <description>A seroprotected subject was defined as a subject with anti-Hepatitis B surface antigen (HBs) antibody concentration greater than or equal to 10 milli-International Units per Milliliter (mIU/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Vaccine Response to MenA, MenC, MenY and MenW-135</measure>
    <time_frame>At 1 month after vaccination with Nimenrix vaccine (Month 1)</time_frame>
    <description>Vaccine response is defined as an rSBA titer of at least 1:32 in subjects initially seronegative [rSBA titer below1:8] and as a 4-fold increase in titer in subjects initially seropositive [rSBA titre greater than or equal to 1:8].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers Above Predefined Cut-off Values</measure>
    <time_frame>Prior to and 1 month after vaccination with Nimenrix vaccine (Months 0 and 1)</time_frame>
    <description>The cut-off values assessed were greater than or equal to (≥) 1:8 and ≥ 1:128.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PSA (Polysaccharide A), Anti-PSC (Polysaccharide C), Anti-PSW-135 (Polysaccharide W-135), and Anti-PSY (Polysaccharide Y) Antibody Concentrations</measure>
    <time_frame>Prior to and 1 month after vaccination with Nimenrix vaccine (Months 0 and 1)</time_frame>
    <description>Concentrations were provided as Geometric Mean Concentrations expressed as micrograms per milliliter (µg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-PSA, Anti-PSC, Anti-PSW-135, and Anti-PSY Antibody Concentrations Above Pre-defined Cut-off Values</measure>
    <time_frame>Prior to and 1 month after vaccination with Nimenrix vaccine (Months 0 and 1)</time_frame>
    <description>The cut-off values assessed include greater than or equal to (≥) 0.3 micrograms per milliliter (µg/mL) and ≥ 2.0 µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Tetanus Toxoid (TT) Antibody Concentrations</measure>
    <time_frame>Prior to and 1 month after vaccination with Nimenrix vaccine (Months 0 and 1)</time_frame>
    <description>Concentrations were provided as Geometric Mean Concentrations expressed as International Units per milliliter (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-tetanus Toxoid Antibody Concentrations Above the Pre-defines Cut-off Value</measure>
    <time_frame>Prior to and 1 month after vaccination with Nimenrix vaccine (Months 0 and 1)</time_frame>
    <description>The cut-off value assessed was greater than or equal to 0.1 International Units per milliliter (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers at Month 7</measure>
    <time_frame>At Month 7</time_frame>
    <description>The rSBA titers were expressed as geometric mean titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers Above Predefined Cut-off Values at Month 7</measure>
    <time_frame>At Month 7</time_frame>
    <description>The cut-off values assessed were greater than or equal to (≥) 1:8 and ≥ 1:128.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations at Month 7</measure>
    <time_frame>At Month 7</time_frame>
    <description>Concentrations were provided as Geometric Mean Concentrations expressed as micrograms per milliliter (µg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations Above Pre-defined Cut-off Values at Month 7</measure>
    <time_frame>At Month 7</time_frame>
    <description>The cut-off values assessed include greater than or equal to (≥) 0.3 micrograms per milliliter (µg/mL) and ≥ 2.0 µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin G (IgG) Anti-HAV Antibody Concentrations</measure>
    <time_frame>Prior to the first dose (Month 0) and 1 month after the third dose of Twinrix vaccine (Month 7)</time_frame>
    <description>Concentrations are given as Geomatric Mean Concentrations expressed as milli-Internatinal Units per Milliliter (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With IgG Anti-HAV Antibody Concentrations Above the Pre-defined Cut-off Value</measure>
    <time_frame>Prior to the first dose (Month 0) and 1 month after the third dose of Twinrix vaccine (Month 7)</time_frame>
    <description>The cut-off value assessed was greater than or equal to 15 milli-Internatinal Units per Milliliter (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG Anti-HBs Antibody Concentrations</measure>
    <time_frame>Prior to the first dose (Month 0) and 1 month after the third dose of Twinrix vaccine (Month 7)</time_frame>
    <description>Concentrations are given as Geomatric Mean Concentrations expressed as milli-Internatinal Units per Milliliter (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With IgG Anti-HB Antibody Concentrations Above the Pre-defined Cut-off Value</measure>
    <time_frame>Prior to the first dose (Month 0) and 1 month after the third dose of Twinrix vaccine (Month 7)</time_frame>
    <description>The cut-off value assessed was greater than or equal to 10 milli-Internatinal Units per Milliliter (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Solicited Local Symptoms Post-meningococcal Vaccination</measure>
    <time_frame>During a 4-day period after Nimenrix vaccination</time_frame>
    <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Solicited Local Symptoms Post-Twinrix Vaccination</measure>
    <time_frame>During a 4-day period after each Twinrix vaccination</time_frame>
    <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Solicited General Symptoms</measure>
    <time_frame>During a 4-day period after any vaccination</time_frame>
    <description>Solicited general symptoms assessed include fatigue, fever (axillary temperature greater than or equal to 37.5 degrees Celcius), gastrointestinal symptoms and headache.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Up to 1 month after each vaccine dose</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Specific AEs of New Onset of Chronic Illnesses</measure>
    <time_frame>During the entire study (up to Month 7)</time_frame>
    <description>Specific AEs of new onset of chronic illnesses include e.g. autoimmune disorders, asthma, type I diabetes and allergies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Rash</measure>
    <time_frame>During the entire study (up to Month 7)</time_frame>
    <description>Rashes include e.g. hives, idiopathic thrombocytopenic purpura, petechiae.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Conditions Prompting Emergency Room Visits</measure>
    <time_frame>During the entire study (up to Month 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Serious Adverse Events (SAEs)</measure>
    <time_frame>During the entire study (up to Month 7)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">611</enrollment>
  <condition>Infections, Meningococcal</condition>
  <arm_group>
    <arm_group_label>Nimenrix + Twinrix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nimenrix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Twinrix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nimenrix (Meningococcal vaccine 134612)</intervention_name>
    <description>Single dose intramuscular injection</description>
    <arm_group_label>Nimenrix Group</arm_group_label>
    <arm_group_label>Nimenrix + Twinrix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Twinrix</intervention_name>
    <description>3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.</description>
    <arm_group_label>Twinrix Group</arm_group_label>
    <arm_group_label>Nimenrix + Twinrix Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they and/or their parents/guardians can
             and will comply with the requirements of the protocol

          -  A male or female between, and including, 11 and 17 years of age at the time of the
             first dose of vaccine.

          -  Written informed consent obtained from the subject/ from the parent or guardian of the
             subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  Previously completed routine childhood vaccinations to the best of his/her/the
             parents'/guardians' knowledge.

          -  If the subject is female and of childbearing potential, she must practice adequate
             contraception for 30 days prior to vaccination, have a negative pregnancy test and
             continue such precautions for two months after completion of the vaccination series.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned
             use during the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the first vaccine dose.

          -  Planned administration/ administration of a vaccine not foreseen by the study protocol
             within one month of the dose of vaccine.

          -  Previous vaccination with meningococcal polysaccharide vaccine of serogroup A, C,
             W-135 and/or Y within the last five years.

          -  Previous vaccination with meningococcal polysaccharide conjugate vaccine of serogroup
             A, C, W-135 and/or Y.

          -  Previous vaccination with tetanus toxoid within the last month.

          -  Previous vaccination with hepatitis A and/or hepatitis B vaccine.

          -  Seropositivity for hepatitis A IgG, hepatitis B surface antigen, hepatitis B core
             antibody and/or hepatitis B surface antigen at screening.

          -  History of hepatitis A, hepatitis B and/or Neisseria meningitidis infection.

          -  Known exposure to hepatitis A and/or hepatitis B virus within three months preceding
             the first dose of study vaccine.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital
             or secondary), including human immunodeficiency virus (HIV) infection, based on
             medical history and physical examination.

          -  A family history of congenital or hereditary immunodeficiency, until the immune
             competence of the potential vaccine recipient is demonstrated.

          -  History of reactions or allergic disease likely to be exacerbated by any component of
             either vaccine.

          -  Major congenital defects or serious chronic illness.

          -  Acute disease at the time of enrolment.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the dose of study vaccine or planned administration during the study period.

          -  Pregnant or lactating female.

          -  History of chronic alcohol consumption and/or drug abuse.

          -  Female planning to become pregnant or planning to discontinue contraceptive
             precautions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karlskrona</city>
        <zip>SE-371 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linköping</city>
        <zip>SE-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malmö</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Umeå</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Örebro</city>
        <zip>SE-701 16</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Østergaard L, Silfverdal SA, Berglund J, Flodmark CE, West C, Bianco V, Baine Y, Miller JM. A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix(®) in subjects aged 11-17 years: an open, randomised, controlled trial. Vaccine. 2012 Jan 17;30(4):774-83. doi: 10.1016/j.vaccine.2011.11.051. Epub 2011 Nov 19.</citation>
    <PMID>22107850</PMID>
  </reference>
  <reference>
    <citation>Ostergaard L et al. The Candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugated vaccine (MenACWY-TT) co-administered with a combined hepatitis A and B vaccine (HepA/B) is immunogenic with an acceptable safety profile in subjects aged 11-17 Years. Abstract presented at the 3rd Northern European Conference on Travel Medicine (NECTM). Hamburg, Germany, 26-29 May 2010.</citation>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2007</study_first_submitted>
  <study_first_submitted_qc>April 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2007</study_first_posted>
  <results_first_submitted>April 23, 2012</results_first_submitted>
  <results_first_submitted_qc>April 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 22, 2012</results_first_posted>
  <disposition_first_submitted>April 27, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>October 1, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 2, 2009</disposition_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-inferiority</keyword>
  <keyword>adolescents</keyword>
  <keyword>meningococcal vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>109063</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109063</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109063</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109063</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109063</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109063</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109063</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nimenrix + Twinrix Group</title>
          <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
        </group>
        <group group_id="P2">
          <title>Nimenrix Group</title>
          <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
        </group>
        <group group_id="P3">
          <title>Twinrix Group</title>
          <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="367"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="367"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nimenrix + Twinrix Group</title>
          <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
        </group>
        <group group_id="B2">
          <title>Nimenrix Group</title>
          <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
        </group>
        <group group_id="B3">
          <title>Twinrix Group</title>
          <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="367"/>
            <count group_id="B2" value="122"/>
            <count group_id="B3" value="122"/>
            <count group_id="B4" value="611"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.3" spread="1.89"/>
                    <measurement group_id="B2" value="14.3" spread="1.84"/>
                    <measurement group_id="B3" value="14.3" spread="1.94"/>
                    <measurement group_id="B4" value="14.3" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="324"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Meningococcal Polysaccharide A Serum Bactericidal Antibodies/Assay, Using Baby Rabbit Complement for Assay (rSBA-MenA), rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers</title>
        <description>The rSBA titers were expressed as geometric mean titers.</description>
        <time_frame>At 1 month after vaccination with Nimenrix vaccine (Month 1)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Nimenrix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Meningococcal Polysaccharide A Serum Bactericidal Antibodies/Assay, Using Baby Rabbit Complement for Assay (rSBA-MenA), rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers</title>
          <description>The rSBA titers were expressed as geometric mean titers.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Nimenrix vaccine.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="360"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA (N= 353; 113; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5263.9" lower_limit="4818.0" upper_limit="5751.0"/>
                    <measurement group_id="O2" value="5211.7" lower_limit="4509.8" upper_limit="6022.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC (N= 360; 115; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4344.6" lower_limit="3800.3" upper_limit="4966.8"/>
                    <measurement group_id="O2" value="4926.9" lower_limit="3684.8" upper_limit="6587.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135 (N= 360; 115; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8922.1" lower_limit="8278.4" upper_limit="9615.9"/>
                    <measurement group_id="O2" value="8987.7" lower_limit="7628.9" upper_limit="10588.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY (N= 360; 115; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9291.5" lower_limit="8537.7" upper_limit="10111.9"/>
                    <measurement group_id="O2" value="9492.8" lower_limit="8172.4" upper_limit="11026.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroconverted for Hepatitis A</title>
        <description>A seroconverted subject was defined as a subject with anti-Hepatitis A virus (HAV) antibody concentration greater than or equal to 15 milli-International Units per Milliliter (mIU/mL) in previously seronegative subjects.</description>
        <time_frame>At 1 month after the third dose of Twinrix vaccine (Month 7)</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on initially seronegative subjects in those groups that received the Twinrix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for Hepatitis A</title>
          <description>A seroconverted subject was defined as a subject with anti-Hepatitis A virus (HAV) antibody concentration greater than or equal to 15 milli-International Units per Milliliter (mIU/mL) in previously seronegative subjects.</description>
          <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on initially seronegative subjects in those groups that received the Twinrix vaccine.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321"/>
                    <measurement group_id="O3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroprotected for Hepatitis B</title>
        <description>A seroprotected subject was defined as a subject with anti-Hepatitis B surface antigen (HBs) antibody concentration greater than or equal to 10 milli-International Units per Milliliter (mIU/mL).</description>
        <time_frame>At 1 month after the third dose of Twinrix vaccine (Month 7)</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Twinrix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroprotected for Hepatitis B</title>
          <description>A seroprotected subject was defined as a subject with anti-Hepatitis B surface antigen (HBs) antibody concentration greater than or equal to 10 milli-International Units per Milliliter (mIU/mL).</description>
          <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Twinrix vaccine.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="327"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Vaccine Response to MenA, MenC, MenY and MenW-135</title>
        <description>Vaccine response is defined as an rSBA titer of at least 1:32 in subjects initially seronegative [rSBA titer below1:8] and as a 4-fold increase in titer in subjects initially seropositive [rSBA titre greater than or equal to 1:8].</description>
        <time_frame>At 1 month after vaccination with Nimenrix vaccine (Month 1)</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Nimenrix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Vaccine Response to MenA, MenC, MenY and MenW-135</title>
          <description>Vaccine response is defined as an rSBA titer of at least 1:32 in subjects initially seronegative [rSBA titer below1:8] and as a 4-fold increase in titer in subjects initially seropositive [rSBA titre greater than or equal to 1:8].</description>
          <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Nimenrix vaccine.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA (N= 261; 84; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC (N= 355; 112; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135 (N= 349; 114; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="346"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY (N= 354; 113; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="335"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers Above Predefined Cut-off Values</title>
        <description>The cut-off values assessed were greater than or equal to (≥) 1:8 and ≥ 1:128.</description>
        <time_frame>Prior to and 1 month after vaccination with Nimenrix vaccine (Months 0 and 1)</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Nimenrix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers Above Predefined Cut-off Values</title>
          <description>The cut-off values assessed were greater than or equal to (≥) 1:8 and ≥ 1:128.</description>
          <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Nimenrix vaccine.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="360"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA ≥ 1:8 [Month 0] (N= 266; 85; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA ≥ 1:8 [Month 1] (N= 353; 113; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC ≥ 1:8 [Month 0] (N= 355; 112; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC ≥ 1:8 [Month 1] (N= 360; 115; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359"/>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135 ≥ 1:8 [Month 0] (N= 349; 114; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135 ≥ 1:8 [Month 1] (N= 360; 115; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY ≥ 1:8 [Month 0] (N= 354; 113; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY ≥ 1:8 [Month 1] (N= 360; 115; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA ≥ 1:128 [Month 0] (N= 266; 85; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA ≥ 1:128 [Month 1] (N= 353; 113; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC ≥ 1:128 [Month 0] (N= 355; 112; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC ≥ 1:128 [Month 1] (N= 360; 115; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135 ≥ 1:128 [Month 0] (N= 349; 114; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135 ≥ 1:128 [Month 1] (N= 360; 115; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY ≥ 1:128 [Month 0] (N= 354; 113; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY ≥ 1:128 [Month 1] (N= 360; 115; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PSA (Polysaccharide A), Anti-PSC (Polysaccharide C), Anti-PSW-135 (Polysaccharide W-135), and Anti-PSY (Polysaccharide Y) Antibody Concentrations</title>
        <description>Concentrations were provided as Geometric Mean Concentrations expressed as micrograms per milliliter (µg/mL).</description>
        <time_frame>Prior to and 1 month after vaccination with Nimenrix vaccine (Months 0 and 1)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, only on those groups of subjects that received Nimenrix. A randomized subset of half of the subjects had sera tested for anti-PSA and anti-PSC antibodies by Enzyme-linked Immunosorbent assay (ELISA) while the other half were tested for anti PSW-135 and anti-PSY antibodies by ELISA.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-PSA (Polysaccharide A), Anti-PSC (Polysaccharide C), Anti-PSW-135 (Polysaccharide W-135), and Anti-PSY (Polysaccharide Y) Antibody Concentrations</title>
          <description>Concentrations were provided as Geometric Mean Concentrations expressed as micrograms per milliliter (µg/mL).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, only on those groups of subjects that received Nimenrix. A randomized subset of half of the subjects had sera tested for anti-PSA and anti-PSC antibodies by Enzyme-linked Immunosorbent assay (ELISA) while the other half were tested for anti PSW-135 and anti-PSY antibodies by ELISA.</population>
          <units>micrograms per milliliter (µg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PSA [Month 0] (N= 176; 55; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.21" upper_limit="0.30"/>
                    <measurement group_id="O2" value="0.24" lower_limit="0.19" upper_limit="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSA [Month 1] (N= 179; 56; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.23" lower_limit="22.91" upper_limit="32.38"/>
                    <measurement group_id="O2" value="18.47" lower_limit="12.02" upper_limit="28.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC [Month 0] (N= 176; 55; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" lower_limit="0.19" upper_limit="0.26"/>
                    <measurement group_id="O2" value="0.26" lower_limit="0.19" upper_limit="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC [Month 1] (N= 180; 55; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.58" lower_limit="15.44" upper_limit="22.37"/>
                    <measurement group_id="O2" value="21.15" lower_limit="14.87" upper_limit="30.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135 [Month 0] (N= 167; 58; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="0.17" upper_limit="0.21"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.15" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135 [Month 1] (N= 178; 58; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78" lower_limit="5.52" upper_limit="8.32"/>
                    <measurement group_id="O2" value="6.72" lower_limit="4.62" upper_limit="9.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY [Month 0] (N= 175; 58; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" lower_limit="0.18" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.14" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY [Month 1] (N= 180; 55; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.04" lower_limit="11.52" upper_limit="17.10"/>
                    <measurement group_id="O2" value="12.50" lower_limit="8.49" upper_limit="18.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-PSA, Anti-PSC, Anti-PSW-135, and Anti-PSY Antibody Concentrations Above Pre-defined Cut-off Values</title>
        <description>The cut-off values assessed include greater than or equal to (≥) 0.3 micrograms per milliliter (µg/mL) and ≥ 2.0 µg/mL.</description>
        <time_frame>Prior to and 1 month after vaccination with Nimenrix vaccine (Months 0 and 1)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, only on those groups of subjects that received Nimenrix. A randomized subset of half of the subjects had sera tested for anti-PSA and anti-PSC antibodies by Enzyme-linked Immunosorbent assay (ELISA) while the other half were tested for anti PSW-135 and anti-PSY antibodies by ELISA.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-PSA, Anti-PSC, Anti-PSW-135, and Anti-PSY Antibody Concentrations Above Pre-defined Cut-off Values</title>
          <description>The cut-off values assessed include greater than or equal to (≥) 0.3 micrograms per milliliter (µg/mL) and ≥ 2.0 µg/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, only on those groups of subjects that received Nimenrix. A randomized subset of half of the subjects had sera tested for anti-PSA and anti-PSC antibodies by Enzyme-linked Immunosorbent assay (ELISA) while the other half were tested for anti PSW-135 and anti-PSY antibodies by ELISA.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PSA ≥ 0.3 µg/mL [Month 0] (N= 176; 55; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSA ≥ 0.3 µg/mL [Month 1] (N= 179; 56; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC ≥ 0.3 µg/mL [Month 0] (N= 176; 55; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC ≥ 0.3 µg/mL [Month 1] (N= 180; 55; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135 ≥ 0.3 µg/mL [Month 0] (N= 176; 58; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135 ≥ 0.3 µg/mL [Month 1] (N= 178; 58; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY ≥ 0.3 µg/mL [Month 0] (N= 175; 58; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY ≥ 0.3 µg/mL [Month 1] (N= 180; 55; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSA ≥ 2.0 µg/mL [Month 0] (N= 176; 55; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSA ≥ 2.0 µg/mL [Month 1] (N= 179; 56; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC ≥ 2.0 µg/mL [Month 0] (N= 176; 55; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC ≥ 2.0 µg/mL [Month 1] (N= 180; 55; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135 ≥ 2.0 µg/mL [Month 0] (N= 176; 58; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135 ≥ 2.0 µg/mL [Month 1] (N= 178; 58; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY ≥ 2.0 µg/mL [Month 0] (N= 175; 58; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY ≥ 2.0 µg/mL [Month 1] (N= 180; 55; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-Tetanus Toxoid (TT) Antibody Concentrations</title>
        <description>Concentrations were provided as Geometric Mean Concentrations expressed as International Units per milliliter (IU/mL).</description>
        <time_frame>Prior to and 1 month after vaccination with Nimenrix vaccine (Months 0 and 1)</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Nimenrix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Tetanus Toxoid (TT) Antibody Concentrations</title>
          <description>Concentrations were provided as Geometric Mean Concentrations expressed as International Units per milliliter (IU/mL).</description>
          <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Nimenrix vaccine.</population>
          <units>International Units per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0 (N= 312; 114; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.800" lower_limit="0.692" upper_limit="0.926"/>
                    <measurement group_id="O2" value="1.020" lower_limit="0.795" upper_limit="1.308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (N= 355; 112; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.794" lower_limit="15.318" upper_limit="18.411"/>
                    <measurement group_id="O2" value="17.252" lower_limit="14.603" upper_limit="20.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-tetanus Toxoid Antibody Concentrations Above the Pre-defines Cut-off Value</title>
        <description>The cut-off value assessed was greater than or equal to 0.1 International Units per milliliter (IU/mL).</description>
        <time_frame>Prior to and 1 month after vaccination with Nimenrix vaccine (Months 0 and 1)</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Nimenrix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-tetanus Toxoid Antibody Concentrations Above the Pre-defines Cut-off Value</title>
          <description>The cut-off value assessed was greater than or equal to 0.1 International Units per milliliter (IU/mL).</description>
          <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Nimenrix vaccine.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0 (N= 312; 114; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (N= 355; 112; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers at Month 7</title>
        <description>The rSBA titers were expressed as geometric mean titers.</description>
        <time_frame>At Month 7</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Nimenrix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers at Month 7</title>
          <description>The rSBA titers were expressed as geometric mean titers.</description>
          <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Nimenrix vaccine.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA (N= 332; 108; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2121.6" lower_limit="1913.5" upper_limit="2352.2"/>
                    <measurement group_id="O2" value="2298.3" lower_limit="1909.0" upper_limit="2767.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC (N= 334; 112; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="952.4" lower_limit="826.2" upper_limit="1097.8"/>
                    <measurement group_id="O2" value="1053.9" lower_limit="803.1" upper_limit="1382.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135 (N= 334; 112; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3283.4" lower_limit="2998.4" upper_limit="3595.4"/>
                    <measurement group_id="O2" value="3497.7" lower_limit="3008.0" upper_limit="4067.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY (N= 334; 112; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4432.7" lower_limit="4027.4" upper_limit="4878.8"/>
                    <measurement group_id="O2" value="4455.6" lower_limit="3821.4" upper_limit="5195.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers Above Predefined Cut-off Values at Month 7</title>
        <description>The cut-off values assessed were greater than or equal to (≥) 1:8 and ≥ 1:128.</description>
        <time_frame>At Month 7</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Nimenrix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers Above Predefined Cut-off Values at Month 7</title>
          <description>The cut-off values assessed were greater than or equal to (≥) 1:8 and ≥ 1:128.</description>
          <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Nimenrix vaccine.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA ≥ 1:8 (N= 332; 108; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC ≥ 1:8 (N= 334; 112; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135 ≥ 1:8 (N= 334; 112; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY ≥ 1:8 (N= 334; 112; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA ≥ 1:128 (N= 332; 108; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC ≥ 1:128 (N= 334; 112; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135 ≥ 1:128 (N= 334; 112; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY ≥ 1:128 (N= 334; 112; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations at Month 7</title>
        <description>Concentrations were provided as Geometric Mean Concentrations expressed as micrograms per milliliter (µg/mL).</description>
        <time_frame>At Month 7</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, only on those groups of subjects that received Nimenrix. A randomized subset of half of the subjects had sera tested for anti-PSA and anti-PSC antibodies by Enzyme-linked Immunosorbent assay (ELISA) while the other half were tested for anti PSW-135 and anti-PSY antibodies by ELISA.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations at Month 7</title>
          <description>Concentrations were provided as Geometric Mean Concentrations expressed as micrograms per milliliter (µg/mL).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, only on those groups of subjects that received Nimenrix. A randomized subset of half of the subjects had sera tested for anti-PSA and anti-PSC antibodies by Enzyme-linked Immunosorbent assay (ELISA) while the other half were tested for anti PSW-135 and anti-PSY antibodies by ELISA.</population>
          <units>micrograms per milliliter (µg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PSA (N= 163; 56; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" lower_limit="3.34" upper_limit="5.15"/>
                    <measurement group_id="O2" value="3.88" lower_limit="2.44" upper_limit="6.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC (N= 164; 56; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" lower_limit="2.60" upper_limit="4.14"/>
                    <measurement group_id="O2" value="4.15" lower_limit="2.59" upper_limit="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135 (N= 167; 56; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" lower_limit="1.99" upper_limit="3.05"/>
                    <measurement group_id="O2" value="3.08" lower_limit="2.11" upper_limit="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY (N= 161; 54; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" lower_limit="2.95" upper_limit="4.78"/>
                    <measurement group_id="O2" value="4.28" lower_limit="2.90" upper_limit="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations Above Pre-defined Cut-off Values at Month 7</title>
        <description>The cut-off values assessed include greater than or equal to (≥) 0.3 micrograms per milliliter (µg/mL) and ≥ 2.0 µg/mL.</description>
        <time_frame>At Month 7</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, only on those groups of subjects that received Nimenrix. A randomized subset of half of the subjects had sera tested for anti-PSA and anti-PSC antibodies by Enzyme-linked Immunosorbent assay (ELISA) while the other half were tested for anti PSW-135 and anti-PSY antibodies by ELISA.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations Above Pre-defined Cut-off Values at Month 7</title>
          <description>The cut-off values assessed include greater than or equal to (≥) 0.3 micrograms per milliliter (µg/mL) and ≥ 2.0 µg/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, only on those groups of subjects that received Nimenrix. A randomized subset of half of the subjects had sera tested for anti-PSA and anti-PSC antibodies by Enzyme-linked Immunosorbent assay (ELISA) while the other half were tested for anti PSW-135 and anti-PSY antibodies by ELISA.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PSA ≥ 0.3 µg/mL (N= 163; 56; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC ≥ 0.3 µg/mL (N= 164; 56; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135 ≥ 0.3 µg/mL (N= 167; 56; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY ≥ 0.3 µg/mL (N= 161; 54; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSA ≥ 2.0 µg/mL (N= 163; 56; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSC ≥ 2.0 µg/mL (N= 164; 56; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSW-135 ≥ 2.0 µg/mL (N= 167; 56; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PSY ≥ 2.0 µg/mL (N= 161; 54; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunoglobulin G (IgG) Anti-HAV Antibody Concentrations</title>
        <description>Concentrations are given as Geomatric Mean Concentrations expressed as milli-Internatinal Units per Milliliter (mIU/mL).</description>
        <time_frame>Prior to the first dose (Month 0) and 1 month after the third dose of Twinrix vaccine (Month 7)</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Twinrix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunoglobulin G (IgG) Anti-HAV Antibody Concentrations</title>
          <description>Concentrations are given as Geomatric Mean Concentrations expressed as milli-Internatinal Units per Milliliter (mIU/mL).</description>
          <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Twinrix vaccine.</population>
          <units>milli-Internatinal Units per Milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0 (N= 333; 0; 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="7.6" upper_limit="8.1"/>
                    <measurement group_id="O3" value="7.6" lower_limit="7.4" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 (N= 331; 0; 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5876.7" lower_limit="5362.9" upper_limit="6439.8"/>
                    <measurement group_id="O3" value="6739.0" lower_limit="5757.4" upper_limit="7887.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With IgG Anti-HAV Antibody Concentrations Above the Pre-defined Cut-off Value</title>
        <description>The cut-off value assessed was greater than or equal to 15 milli-Internatinal Units per Milliliter (mIU/mL).</description>
        <time_frame>Prior to the first dose (Month 0) and 1 month after the third dose of Twinrix vaccine (Month 7)</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Twinrix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With IgG Anti-HAV Antibody Concentrations Above the Pre-defined Cut-off Value</title>
          <description>The cut-off value assessed was greater than or equal to 15 milli-Internatinal Units per Milliliter (mIU/mL).</description>
          <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Twinrix vaccine.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0 (N= 333; 0; 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 (N= 331; 0; 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IgG Anti-HBs Antibody Concentrations</title>
        <description>Concentrations are given as Geomatric Mean Concentrations expressed as milli-Internatinal Units per Milliliter (mIU/mL).</description>
        <time_frame>Prior to the first dose (Month 0) and 1 month after the third dose of Twinrix vaccine (Month 7)</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Twinrix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>IgG Anti-HBs Antibody Concentrations</title>
          <description>Concentrations are given as Geomatric Mean Concentrations expressed as milli-Internatinal Units per Milliliter (mIU/mL).</description>
          <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Twinrix vaccine.</population>
          <units>milli-Internatinal Units per Milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0 (N= 333; 0; 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.6" upper_limit="1.7"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.6" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 (N= 330; 0; 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6088.2" lower_limit="4977.5" upper_limit="7446.7"/>
                    <measurement group_id="O3" value="7654.7" lower_limit="5518.8" upper_limit="10617.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With IgG Anti-HB Antibody Concentrations Above the Pre-defined Cut-off Value</title>
        <description>The cut-off value assessed was greater than or equal to 10 milli-Internatinal Units per Milliliter (mIU/mL).</description>
        <time_frame>Prior to the first dose (Month 0) and 1 month after the third dose of Twinrix vaccine (Month 7)</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Twinrix vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With IgG Anti-HB Antibody Concentrations Above the Pre-defined Cut-off Value</title>
          <description>The cut-off value assessed was greater than or equal to 10 milli-Internatinal Units per Milliliter (mIU/mL).</description>
          <population>The analysis was performed on the According-to-Protocol cohort for immunogenicity including all evaluable subjects for whom immunogenicity data were available for the considered time point(s), only on those groups of subjects that received the Twinrix vaccine.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0 (N= 333; 0; 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 (N= 330; 0; 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="327"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Solicited Local Symptoms Post-meningococcal Vaccination</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
        <time_frame>During a 4-day period after Nimenrix vaccination</time_frame>
        <population>The analysis was done on the Total Vaccinated Cohort including all subjects with study vaccine administered and with a completed symptom sheet. Only subjects from the groups receiving Nimenrix were assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Solicited Local Symptoms Post-meningococcal Vaccination</title>
          <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
          <population>The analysis was done on the Total Vaccinated Cohort including all subjects with study vaccine administered and with a completed symptom sheet. Only subjects from the groups receiving Nimenrix were assessed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="365"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Solicited Local Symptoms Post-Twinrix Vaccination</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
        <time_frame>During a 4-day period after each Twinrix vaccination</time_frame>
        <population>The analysis was done on the Total Vaccinated Cohort including all subjects with study vaccine administered and with a completed symptom sheet. Only subjects from the groups receiving Twinrix were assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Solicited Local Symptoms Post-Twinrix Vaccination</title>
          <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
          <population>The analysis was done on the Total Vaccinated Cohort including all subjects with study vaccine administered and with a completed symptom sheet. Only subjects from the groups receiving Twinrix were assessed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include fatigue, fever (axillary temperature greater than or equal to 37.5 degrees Celcius), gastrointestinal symptoms and headache.</description>
        <time_frame>During a 4-day period after any vaccination</time_frame>
        <population>The analysis was done on the Total Vaccinated Cohort including all subjects with study vaccine administered and with a completed symptom sheet.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed include fatigue, fever (axillary temperature greater than or equal to 37.5 degrees Celcius), gastrointestinal symptoms and headache.</description>
          <population>The analysis was done on the Total Vaccinated Cohort including all subjects with study vaccine administered and with a completed symptom sheet.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>Up to 1 month after each vaccine dose</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="NA">Subjects in the Nimenrix Group only received 1 dose of vaccine. Hence, no results are available for Post Dose 2.</measurement>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="NA">Subjects in the Nimenrix Group only received 1 dose of vaccine. Hence, no results are available for Post Dose 3.</measurement>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Specific AEs of New Onset of Chronic Illnesses</title>
        <description>Specific AEs of new onset of chronic illnesses include e.g. autoimmune disorders, asthma, type I diabetes and allergies.</description>
        <time_frame>During the entire study (up to Month 7)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Specific AEs of New Onset of Chronic Illnesses</title>
          <description>Specific AEs of new onset of chronic illnesses include e.g. autoimmune disorders, asthma, type I diabetes and allergies.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Rash</title>
        <description>Rashes include e.g. hives, idiopathic thrombocytopenic purpura, petechiae.</description>
        <time_frame>During the entire study (up to Month 7)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Rash</title>
          <description>Rashes include e.g. hives, idiopathic thrombocytopenic purpura, petechiae.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Conditions Prompting Emergency Room Visits</title>
        <time_frame>During the entire study (up to Month 7)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Conditions Prompting Emergency Room Visits</title>
          <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>During the entire study (up to Month 7)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Nimenrix + Twinrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix Group</title>
            <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
          </group>
          <group group_id="O3">
            <title>Twinrix Group</title>
            <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events were reported throughout the entire study period (up to Month 7). Other Frequent (non-serious) Adverse Events were reported during a 4-day follow-up period after any vaccine dose.</time_frame>
      <desc>Other Frequent (non-serious) Adverse Events were reported only for those subjects who received the vaccination and completed their symptom sheet.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nimenrix + Twinrix Group</title>
          <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
        </group>
        <group group_id="E2">
          <title>Nimenrix Group</title>
          <description>Subjects received 1 dose of Nimenrix™ vaccine at Month 0.</description>
        </group>
        <group group_id="E3">
          <title>Twinrix Group</title>
          <description>Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="367"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="228" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain at the injection site</sub_title>
                <description>Post-meningococcal vaccination</description>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="365"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Swelling at the injection site</sub_title>
                <description>Post-meningococcal vaccination</description>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="365"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Redness at the injection site</sub_title>
                <description>Post-meningococcal vaccination</description>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="365"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pain at the injection site</sub_title>
                <description>Post-Twinrix vaccination</description>
                <counts group_id="E1" subjects_affected="228" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Swelling at the injection site</sub_title>
                <description>Post-Twinrix vaccination</description>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Redness at the injection site</sub_title>
                <description>Post-Twinrix vaccination</description>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

